St Antonius Hospital in Nieuwegein, the Netherlands, uses a soluble interleukin-2 receptor (sIL-2R) ELISA from Tecan in the investigation, management and monitoring of interstitial lung disease. This easy-to-use assay is the world’s first IVDR-compliant ELISA for the quantification of sIL-2R levels, and is supplied complete with the internal controls necessary to provide reliable measurements and distinguish between different types of interstitial lung disease.
The quantification of unique proteins within biological samples has traditionally required thousands, tens of thousands or even millions of cells, with no way to identify cellular heterogeneity within the populations. To overcome this issue, researchers at Brigham Young University have been evaluating the potential of single-cell dispensing to allow proteomic analysis of individual cells.
The vaccine development process has transformed dramatically in recent years, driven by the urgent need for effective immunization against emerging contagious diseases. Traditional pipelines for the creation of novel vaccines relied on more than 10 years of research, preclinical investigations and clinical trials, but advanced laboratory technologies have led the way to rapid vaccine development, production and upscaling. Automation has enabled vaccine research to go beyond the bounds of what was previously possible in terms of reliability and throughput, leading to faster progress and new ways of designing experiments. The Vaccines Global Bioprocess Development Platform at Sanofi has recently automated its miniaturized chromatography workflows to speed up downstream processing, achieving even greater productivity and efficiency for the company’s workflows.